RT @ericdeinmd: #ACR21 L19: TitAIN: Secukinumab for GCA âï¸Phase 2 study with n=52 âï¸70% of SEC sustained remissi
Tweet Content
#ACR21 L19: TitAIN: Secukinumab for GCA
⭐️Phase 2 study with n=52
⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8%
⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g)
- Looking forward to larger study
@Rheumnow
https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off